A5052429760- Helicobacter pylori-related gastroenterology studies
- Bacterial Identification and Susceptibility Testing
- Antimicrobial Resistance in Staphylococcus
- Gastroesophageal reflux and treatments
- Eosinophilic Esophagitis
- Antibiotics Pharmacokinetics and Efficacy
- Antifungal resistance and susceptibility
- Microscopic Colitis
- Nausea and vomiting management
- Antibiotic Use and Resistance
- Inflammatory Bowel Disease
- Gastrointestinal motility and disorders
- Fungal Infections and Studies
- Pneumonia and Respiratory Infections
- Respiratory and Cough-Related Research
- Urinary Tract Infections Management
- Antibiotic Resistance in Bacteria
- Chronic Obstructive Pulmonary Disease (COPD) Research
- COVID-19 Clinical Research Studies
- Streptococcal Infections and Treatments
- Pharmaceutical Practices and Patient Outcomes
- Clostridium difficile and Clostridium perfringens research
- Microbial Metabolites in Food Biotechnology
- Long-Term Effects of COVID-19
- Pathogenesis and Treatment of Hiccups
Eugene Applebaum College of Pharmacy and Health Sciences
2013-2025
Wayne State University
2016-2025
St. John Hospital & Medical Center
2015-2024
Henry Ford Hospital
2024
Jefferson Healthcare
2019
St. John's Hospital
2019
Indianapolis Zoo
2016
American College of Clinical Pharmacy
2016
University of North Carolina at Pembroke
2016
Harper University Hospital
2007-2011
Abstract Background Evusheld® is a combination of two monoclonal antibodies, Tixagevimab and Cilgavimab. It was developed for the pre-exposure prophylaxis (PrEP) treatment COVID-19 illness those who are immunocompromised. There paucity long-term real-world data on use Evusheld among immunosuppressed patients against SARS-CoV-2 Omicron variants. Methods A retrospective cohort chart review 18 years older received dose regimen from December 1, 2021 to January 31, 2023 at community teaching...
Abstract Background Acinetobacter baumannii (ABM) is a gram-negative coccobacillus associated with infections in healthcare facilities and has high mortality rate. Guidelines recommend nine grams ampicillin/sulbactam (amp/sulb) every eight hours for moderate to severe ABM infections. We assessed the dosing effectiveness of amp/sulb treatment pneumonia bacteremia. Methods conducted retrospective cohort study patients receiving dose (≥ 3.1 gms q4h or CrCl < 30mL/min) compared low...
Background: Heart failure (HF) transition of care (TOC) programs may improve continuity and coordination decrease hospital readmissions. Objective: This study evaluated the impact pharmacy-led HF TOC on readmission rate. Methods: was a single-center, pre-post quasi-experimental study. Pharmacy comprised admission discharge medication reconciliations patient education. Patients were included if they had primary diagnosis. excluded admitted for non-HF diagnosis, <24 hours, stage IV cancer...
Abstract Management of invasive fungal infections is challenging with growing antifungal resistance. Broad use has resulted in greater intrinsic and acquired resistance among Candida spp. It important for clinicians to recognize the relationship between host susceptibility, site infection, profiles, specific drug pharmacokinetics pharmacodynamics, role novel agents. This narrative review covers rezafungin, ibrexafungerp, fosmanogepix management candidiasis (IC). The PubMed Database, Embase,...